
RNA Technologies & Therapeutics RNA T&T is a recognized and leading biotechnology company specializing in the design, optimization, synthesis and delivery of high-quality RNA-based therapeutics as well as well as targeted lipid nanoparticles (LNP). RNA T&T has developed a proprietary platform and significant knowhow to design high expressing mRNA molecules—generating as much as 10x greater protein with large and complex RNA sequences when compared to current codon optimization models. Our focus is to support clinicians, and companies develop their products by providing full in-house services including CMC strategy, manufacturing and analytical development, IND-enabling activities and cGMP manufacturing to support N=1 trials, rare disease and Phase 1/2 clinical trials. RNA T&T’s expertise was used for the design of the gene therapy developed for BABY KJ and our company continues to support N=1 initiatives across biotech & clinician-initiated trials. In addition to the team’s proven expertise in the design, development and manufacturing of RNA based therapies (mRNA, lcRNA, siRNA, etc) for CGT therapies, RNA technologies offer the largest ready-to-go (of-the shelf) catalogue of codon optimized payloads encoding for gene editing and genome engineering tools, in vivo CAR-Ts, reporters and other genes of interest. Our goal is to be the go-to RNA CDMO providing consistently high-quality cost-effective solutions for all patients. CDMO

RNA Technologies & Therapeutics

RNA T&T is a recognized and leading biotechnology company specializing in the design, optimization, synthesis and delivery of high-quality RNA-based therapeutics as well as well as targeted lipid nanoparticles (LNP). RNA T&T has developed a proprietary platform and significant knowhow to design high expressing mRNA molecules—generating as much as 10x greater protein with large and complex RNA sequences when compared to current codon optimization models. Our focus is to support clinicians, and companies develop their products by providing full in-house services including CMC strategy, manufacturing and analytical development, IND-enabling activities and cGMP manufacturing to support N=1 trials, rare disease and Phase 1/2 clinical trials. RNA T&T’s expertise was used for the design of the gene therapy developed for BABY KJ and our company continues to support N=1 initiatives across biotech & clinician-initiated trials. In addition to the team’s proven expertise in the design, development and manufacturing of RNA based therapies (mRNA, lcRNA, siRNA, etc) for CGT therapies, RNA technologies offer the largest ready-to-go (of-the shelf) catalogue of codon optimized payloads encoding for gene editing and genome engineering tools, in vivo CAR-Ts, reporters and other genes of interest. Our goal is to be the go-to RNA CDMO providing consistently high-quality cost-effective solutions for all patients.

CDMO